Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE
NCT05851391Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Aug 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in status epilepticus (SE) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Post-cardiac arrest refractory status epilepticus control at 48 hours. Started Aug 2023; status: recruiting.
02
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT05851391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851391.